Cancer vaccines could be the next big thing in medicine

Key Points:

• Molly Hones, diagnosed with rare stage 4 fibrolamellar carcinoma, achieved full remission within five months after joining a trial for an experimental off-the-shelf cancer vaccine, marking a significant breakthrough in cancer treatment.
• Cancer vaccines, unlike chemotherapy and radiation, stimulate the immune system to recognize and destroy cancer cells, offering the potential for long-lasting remission and even cure by teaching the body to fight cancer on its own.
• Moderna's personalized cancer vaccine for melanoma recently succeeded in Phase 3 trials and could be FDA-approved as early as next year, with ongoing tests for other cancers including lung, bladder, kidney, pancreas, and stomach.
• Personalized cancer vaccines are tailored to a patient's unique tumor mutations but are currently expensive and complex to produce, while off-the-shelf vaccines target common abnormalities in specific cancers, as in Hones's case.
• Although still mostly in clinical trials, cancer vaccines combined with other therapies show promise in improving treatment efficacy, with researchers developing diverse platforms like mRNA, DNA, and viral vectors to expand their reach and impact.